The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes
Open accessAbstract
OBJECTIVE: This trial compared the efficacy and safety of the first oral glucagon-like peptide 1 (GLP-1) receptor agonist, oral semaglutide, as monotherapy with placebo in patients with type 2 diabetes managed by diet and exercise alone. Two estimands addressed two efficacy-related questions: a treatment policy estimand (regardless of trial product discontinuation or rescue medication use) and a trial product estimand (on trial product without rescue medication use) in all randomized patients. RESEARCH DESIGN AND METHODS: This was a 26-week, phase 3a, randomized, double-blind, placebo-controlled, parallel-group trial conducted in 93 sites in nine countries. Adults with type 2 diabetes insufficiently controlled with diet and exercise were randomized (1:1:1:1) to once-daily oral semaglutide 3 mg, 7 mg, 14 mg, or placebo. The primary end point was change from baseline to week 26 in HbA1c. The confirmatory secondary end point was change from baseline to week 26 in body weight. RESULTS: In the 703 patients randomized (mean age 55 years, 50.8% male, and mean baseline HbA1c 8.0% [64 mmol/mol]), oral semaglutide reduced HbA1c (placebo-adjusted treatment differences at week 26: treatment policy estimand, −0.6% [3 mg], −0.9% [7 mg], and −1.1% [14 mg]; trial product estimand, −0.7% [3 mg], −1.2% [7 mg], and −1.4% [14 mg]; P < 0.001 for all) and body weight (treatment policy, −0.1 kg [3 mg], −0.9 kg [7 mg], and −2.3 kg [14 mg, P < 0.001]; trial product, −0.2 kg [3 mg], −1.0 kg [7 mg, P = 0.01], and −2.6 kg [14 mg, P < 0.001]). Mild-to-moderate transient gastrointestinal events were the most common adverse events with oral semaglutide. Trial product discontinuations occurred in 2.3–7.4% with oral semaglutide and 2.2% with placebo. CONCLUSIONS: In patients with type 2 diabetes, oral semaglutide monotherapy demonstrated superior and clinically relevant improvements in HbA1c (all doses) and body weight loss (14 mg dose) versus placebo, with a safety profile consistent with other GLP-1 receptor agonists.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Therapies shown to positively affect albuminuria and declining eGFR include ACE inhibitors, ARBs, SGLT2is, GLP-1 RAs, and the nonsteroidal mineralocorticoid antagonist finerenone.197,209,239,242,393,423–435”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [424]
In the citing paper
“Empagliflozin and canagliflozin demonstrated reduction in MACE in CVOTs; empagliflozin also demonstrated decreased CV death and all-cause mortality.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [424]
In the citing paper
“Empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin have shown a decrease in hospitalization for HF in their CVOTs.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [424]
In the citing paper
“Dapagliflozin based on the DAPA-CKD RCT424 has received an FDA indication to reduce the risk of sustained eGFR decline, end-stage kidney disease, CV death, and hospitalization for HF in adults with CKD at risk of progression.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [424]
In the citing paper
“Multiple studies have shown renal and CV benefits of SGLT2is239,424–426,444,1052–1054”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [424]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,265
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Reproductive Health and Human Rights · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,769
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationStatistical Analysis With Missing Data
Ghosh, S. (1988) · Technometrics · doi:10.1080/00401706.1988.10488446 · Cited by 4,576
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
International Conference on Harmonisation
Guy, R. C. (2014) · Encyclopedia of Toxicology · doi:10.1016/b978-0-12-386454-3.00861-7 · Cited by 1,478
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 2×
“†Severe hypoglycemia was defined according to the American Diabetes Association classification (16) (requiring assistance of another person to actively administer carbohydrateor glucagonor takeother correctiveactions).”
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745 · cited 2×
“The safety profile of oral semaglutide was generally consistent with that reported for subcutaneous semaglutide (19)”
8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s008 · Cited by 699
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetologia · doi:10.1007/s00125-014-3460-0 · Cited by 694
Transcellular Stomach Absorption of a Derivatized Glucagon-Like Peptide-1 Receptor Agonist
Buckley, S. T., Bækdal, T. A., Vegge, A., Maarbjerg, S. J., Pyke, C., Ahnfelt-Rønne, J., Madsen, K. G., Schéele, S. G., Alanentalo, T., Kirk, R. K., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar7047 · Cited by 553 · cited 1×
“including facilitating the passage of semaglutide across the gastric epithelium via a transcellular mechanism, as well as providing a localized increase in pH to protect semaglutide from proteolytic degradation (8).”
Davies, M., Pieber, T. R., Hartoft-Nielsen, M.-L., Hansen, O. K. H., Jabbour, S., & Rosenstock, J. (2017) · JAMA · doi:10.1001/jama.2017.14752 · Cited by 506 · cited 6×
“Oral semaglutide is developed as a tablet, coformulated with the absorption enhancer sodium N-(8-[2-hydroxylbenzoyl] amino) caprylate (SNAC) (7).”
InfluentialSelf-citationRosenstock, J., Allison, D., Birkenfeld, A. L., Blicher, T. M., Deenadayalan, S., Jacobsen, J. B., Serusclat, P., Violante, R., Watada, H., Davies, M., et al. (2019) · JAMA · doi:10.1001/jama.2019.2942 · Cited by 421
Self-citationHtike, Z. Z., Zaccardi, F., Papamargaritis, D., Webb, D. R., Khunti, K., & Davies, M. J. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12849 · Cited by 416
Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403 · cited 1×
“Peptide-based drugs, including GLP-1 receptor agonists, typically have very low bioavailability when administered orally due to extensive degradation by proteolytic enzymes and poor absorption across the gastrointestinal mucosa (5,6).”
Emerging Trends in Oral Delivery of Peptide and Protein Drugs
Mahato, R. I., Narang, A. S., Thoma, L., & Miller, D. D. (2003) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v20.i23.30 · Cited by 352 · cited 1×
“Peptide-based drugs, including GLP-1 receptor agonists, typically have very low bioavailability when administered orally due to extensive degradation by proteolytic enzymes and poor absorption across the gastrointestinal mucosa (5,6).”
Granhall, C., Donsmark, M., Blicher, T. M., Golor, G., Søndergaard, F. L., Thomsen, M., & Bækdal, T. A. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0728-4 · Cited by 190 · cited 1×
“The pharmacokinetics of oral semaglutide have been established in healthy subjects and subjects with type 2 diabetes and support once-daily dosing (9).”
Bretz, F., Posch, M., Glimm, E., Klinglmueller, F., Maurer, W., & Rohmeyer, K. (2011) · Biometrical Journal · doi:10.1002/bimj.201000239 · Cited by 172 · cited 1×
“The confirmation of efficacy of oral semaglutide on change in HbA1c and in body weight both from baseline to week 26 was based on a weighted Bonferroni closed-testing strategy (17) to control the overall type 1 error for the hypotheses evaluated by the treatment policy estimand (see Supplementary Appendix 3 for detail…”
Lando, H. M., Alattar, M., & Dua, A. P. (2012) · Endocrine Practice · doi:10.4158/ep11290.or · Cited by 102
Steinberg, W. M., Buse, J. B., Ghorbani, M. L. M., Ørsted, D. D., Nauck, M. A., the LEADER Steering Committee, & on behalf of the LEADER Trial Investigators (2017) · Diabetes Care · doi:10.2337/dc16-2747 · Cited by 87
Chen, Y. H., Huang, C., Cho, Y. M., Li, P., Gu, L., Wang, F., Yang, J., & Wang, W. Q. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13340 · Cited by 46
Nauck, M. A., Frossard, J.-L., Barkin, J. S., Anglin, G., Hensley, I. E., Harper, K. D., & Milicevic, Z. (2017) · Diabetes Care · doi:10.2337/dc16-0984 · Cited by 36
Cited by
Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01324-6 · Cited by 1,080
Self-citationAdvances in oral peptide therapeutics
Drucker, D. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0053-0 · Cited by 646
Yao, H., Zhang, A., Li, D., Wu, Y., Wang, C.-Z., Wan, J.-Y., & Yuan, C.-S. (2024) · BMJ · doi:10.1136/bmj-2023-076410 · Cited by 558
Marx, N., Husain, M., Lehrke, M., Verma, S., & Sattar, N. (2022) · Circulation · doi:10.1161/circulationaha.122.059595 · Cited by 483
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Metadata
- Authors
- Aroda, V. R., Rosenstock, J., Terauchi, Y., Altuntas, Y., Lalic, N. M., Morales Villegas, E. C., Jeppesen, O. K., Christiansen, E., Hertz, C. L., Haluzík, M., PIONEER 1 Investigators, Belkacem, K., Chiali, N., Bourezane, S., Guermaz, R., Popivanov, P., Lefterov, I., Tankova, T., Penchev, I., Koskova, M., Hudcova, M., Vesela, A., Rancova, A., Haluzik, M., Kiyosue, A., Matsuoka, O., Inoue, S., Terauchi, Y., Fukushima, Y., Ide, Y., Violante Ortiz, R. M., Morales Villegas, E., Golovach, A., Alpenidze, D., Frolova, E., Zhdanova, E., Ruyatkina, L., Ershova, O., Samoilova, Y., Zyangirova, S., Lalic, K., Lalic, N., Beljic Zivkovic, T., Ataoglu, E., Bakiner, O., Dayan, A., Sargin, M., Mert, M., Adas, M., Tabak, O., Altuntas, Y., Murray, A., Iranmanesh, A., Schlau, A., Wieskopf, B., Snyder, B., Griffin, C., Fogarty, C., Lovell, C., Allison, D., Fitz-Patrick, D., Grant, D., Klonoff, D., Williams, D., Armas, E., Palace, E., Ruoff, G., Martinez, G., Perez, G., Bays, H., Tatu, H., Maynard, J., Cedeno, J.-E., Aroda, V., Park, J., Sutton, J., Pouzar, J., Bertsch, J., Condit, J., Serje, J., Cabaccan, J., Risser, J., Frias, J., Rosenstock, J., Sivalingam, K., Maw, K., Hanson, L., Billings, L., Connery, L., Juarez, M., Lillestol, M., Fraser, N., Beckett, P., Wade, R., Gaona, R., Jackson, R., DeLuca, R., Alpizar, S., Herring, S., Stringam, S., Bauer, S., Gangi, S., Sligh, T., Jarrett, W., & Fitzgibbons, W.
- Affiliations
- Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
- Clinic for Endocrinology, Diabetes and Metabolic Diseases, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
- Cardiometabolic Research Center, Aguascalientes, Mexico
- Novo Nordisk (Denmark) (DK)
- Institute for Clinical and Experimental Medicine and Institute for Endocrinology, Prague, Czech Republic
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-06-11
- Volume
- 42
- Issue
- 9
- Pages
- 1724-1732
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2951522032
- Cited by
- 493
- References
- 23
- Citations by year
- 2026: 60 · 2025: 107 · 2024: 91 · 2023: 56 · 2022: 53 · 2021: 55 · 2020: 57 · 2019: 13
- FWCI
- 36.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- oral semaglutide, type 2 diabetes, GLP-1 receptor agonists, monotherapy, HbA1c, glycemic control, weight loss, treatment policy estimand, gastrointestinal adverse effects, drug discontinuation, dose comparison, treatment efficacy and safety
- MeSH terms
- Semaglutide, Administration, Oral, Adult, Diabetes Mellitus, Type 2, Diet, Double-Blind Method, Glucagon-Like Peptides, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Weight Loss, Exercise
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.